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Abstract
Background: Myofascial pain is a common dysfunction with a lifetime prevalence affecting up to 85% of the
general population. Current guidelines for the management of myofascial pain are not available. In this study we
investigated how physicians on the basis of prescription behaviour evaluate the effectiveness of treatment options
in their management of myofascial pain.
Methods: We conducted a cross-sectional, nationwide survey with a standardized questionnaire among 332
physicians (79.8% male, 25.6% female, 47.5 ± 9.6 years) experienced in treating patients with myofascial pain.
Recruitment of physicians took place at three German meetings of pain therapists, rheumatologists and
orthopaedists, respectively. Physicians estimated the prevalence of myofascial pain amongst patients in their
practices, stated what treatments they used routinely and then rated the perceived treatment effectiveness on a
six-point scale (with 1 being excellent). Data are expressed as mean ± standard deviation.
Results: The estimated overall prevalence of active myofascial trigger points is 46.1 ± 27.4%. Frequently prescribed
treatments are analgesics, mainly metamizol/paracetamol (91.6%), non-steroidal anti-inflammatory drugs/coxibs
(87.0%) or weak opioids (81.8%), and physical therapies, mainly manual therapy (81.1%), TENS (72.9%) or
acupuncture (60.2%). Overall effectiveness ratings for analgesics (2.9 ± 0.7) and physical therapies were moderate
(2.5 ± 0.8). Effectiveness ratings of the various treatment options between specialities were widely variant. 54.3% of
all physicians characterized the available treatment options as insufficient.
Conclusions: Myofascial pain was estimated a prevalent condition. Despite a variety of commonly prescribed
treatments, the moderate effectiveness ratings and the frequent characterizations of the available treatments as
insufficient suggest an urgent need for clinical research to establish evidence-based guidelines for the treatment of
myofascial pain syndrome.
Background
Myofascial pain syndrome is a chronic muscular pain
disorder in one muscle or groups of muscles accompa-
nied by local and referred pain, decreased range of
motion, weakness, and often autonomic phenomena. It
is a primary cause of health-care visits, absenteeism and
invalidity pensions [1].
Myofascial pain affects up to 85% of the general popu-
lation [2]. Myofascial trigger points play a central role in
the pathophysiology of common myofascial pain syn-
dromes [3]. Myofascial trigger points are defined as
hyperirritable spots, usually within a taut band of skele-
tal muscle or in the muscle fascia, which is painful on
compression and can give rise to characteristic referred
pain, motor dysfunction, and autonomic phenomena [2].
Moreover, abnormal spontaneous electrical activities
have been described at these sites [4]. Several
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involved in these ectopic pain mechanisms [5,6] and
were found to be significantly higher in active trigger
points [5]. Neuroplastic remodelling has been shown in
the peripheral and central nerve system [7]. However,
the understanding of the neurophysiologic genesis of
trigger points and their role in myofascial pain syn-
drome remains a present focus of research [8].
Treatment approaches in myofascial pain range from
analgesics to various physical modalities. These
approaches include combined techniques (e.g. spray and
stretch), manual techniques, transcutaneous electrical
stimulation (TENS), frequency-modulated neural stimu-
lation, ultrasound or massage, injections, acupuncture
and dry needling [9-14]. Analgesics are often used in
the treatment of myofascial pain [15]. Despite the vari-
ety of treatment approaches, there is a lack of clinical
evidence to guide treatment. There is moderate evidence
suggesting that back schools reduce pain in an occupa-
tional setting and improve function and return-to-work
status [16]. Acupuncture and dry-needling may be useful
adjuncts [13,17-20]. Trigger point injections remain the
treatment with the most scientific support [18,20,21].
Various injected substances have been investigated.
These include local anaesthetics, botulinum toxin, sterile
water and sterile saline [15,17,18,21,22]. Despite, data
does neither favour injection of any substance in parti-
cular over injection of an inert substance, nor are injec-
tions (wet needling) superior to dry needling [18,20,23].
The available data do explicitly not support the use of
b o t u l i n u mt o x i ni n j e c t i o ni nt r i g g e rp o i n t sf o rm y o f a s -
cial pain [21,22].
In conclusion there is not sufficient clinical evidence
to incorporate evidence-based guide treatments.
We therefore evaluated the distribution of the usage
and physicians rating of effectiveness for frequently pre-
scribed treatments amongst German physicians with
experience in treating patients with myofascial pain.
Methods
Design and setting
We conducted a cross-sectional, nationwide survey
among German physicians involved in the management
of patients with myofascial pain. Participants were
recruited at the annual meetings of the German Society
for the Study of Pain, German chapter of the IASP
[Deutsche Gesellschaft zum Studium des Schmerzes],
the Professional Organisation of German Rheumatolo-
gists [Berufsverband Deutscher Rheumatologen] and the
Association of Southern German Orthopaedists [Verei-
nigung Süddeutscher Orthopäden]. Participants com-
pleted a standardised questionnaire.
A subgroup analysis was performed within three
groups of all physicians. We chose pain therapists,
orthopaedists and rheumatologists as they were thought
to be the ones with most experience in attending and
treating myofascial pain syndrome.
Ethics
In this trial we consider the ethical, legal and regula-
tory norms and standards for research involving
human subjects in Germany. As this study did not
involve patient data and the research did not involve
humans, ethical approval was not necessary http://
www.wma.net/en/30publications/10policies/b3/index.
html. Written consent was not sought from each parti-
cipant for use of survey data, but consent of respon-
dents was assumed if they completed and returned the
questionnaire.
Questionnaire (additional file 1)
Demographic and participants characteristics
In the first part we assessed the following demographic
data: age, gender, field of specialisation (surgery, internal
medicine, anaesthesiology, neurology and orthopaedics),
subspecialisation (pain therapy, rheumatology and trau-
matology), employment centre (university hospital,
county hospital, private clinic and pain centre), and sta-
tus of specialisation (resident and consultant). We asked
for the physician’s average number of treated myofascial
pain patients and the number of patients referred to
specialised pain centres.
Estimated importance of myofascial pain syndrome and
prevalence of myofascial trigger points
Secondly we wanted the physicians to estimate the
importance of myofascial pain in the general population
o nas i x - p o i n ts c a l e( w i t h1b e i n gav e r yc o m m o np r o -
blem). Additionally the physicians had to estimate the
prevalence of active trigger points in the population and
their respective patients in percent.
Prescription rates and rating of treatment options
Physicians were asked to cho o s et h e i rr o u t i n e l yp r e -
scribed therapeutic options in the treatment of myofas-
cial pain syndrome from a list of prespecified options.
Afterwards they had to rate the effectiveness of the
approaches chosen based on their own experience on a
six-point scale (with 1 being “excellently effective” and 6
being “ineffective”). We asked for analgesics (non-steroi-
dal anti-inflammatory drugs/coxibs, metamizol/paraceta-
mol, weak and strong opioids, anticonvulsants,
antidepressants,), physical medicine (TENS, manual
therapy, ultrasound, percussion waves, acupuncture, dry
needling) and injections (spinal interventions, injection
of botulinum toxin or local anaesthetics). In each cate-
gory, physicians had the opportunity to name additional
treatment approaches (free text). Finally, we asked for
the opinion regarding the sufficiency of available treat-
ment options.
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All statistical analysis wasc a r r i e do u tu s i n gt h eS P S S
statistical software system (SPSS Inc., Chicago, IL; ver-
sion 15.0). Data were expressed as mean ± SD.
Between-group differences were examined with Kruskal-
Wallis tests, using the Mann-Whitney U tests for post-
hoc two-group comparisons. Two-sided p < 0.05 were
considered statistically significant. Due to the explora-
tory nature of our analyses, no alpha adjustments for
multiple testing were undertaken.
Results
Demographic and participants characteristics
Three hundred thirty-two physicians with a mean age of
47.5 ± 9.6 years (85 female, 25.6%, 43.6 ± 9.2 years; 235
male, 70.8%, 48.8 ± 9.4 years) responded to the ques-
tionnaire. Among all physicians, 146 (44.0%) were ortho-
paedists, 97 (29.2%) internists and 63 (19.0%)
anaesthetists. Out of these groups, 90 (27.1%) were sub-
specialised in rheumatology and 50 (15.1%) in pain ther-
apy. Thirty-seven (11.1%) doctors worked at a university
hospital, 113 (34.0%) at a county hospital, 160 (48.2%)
in a private clinic, 2 (0.6%) in a pain centre and 20
(6.0%) did not specify their place of work. Forty-one
(12.3%) physicians were residents and 281 (84.6%) con-
sultants. The detailed affiliations and professional status
o ft h er e s p o n d e n t sa r es h o w ni nT a b l eS 1( a d d i t i o n a l
file 2).
Congress groups showed differences regarding age,
gender and the work centre. Female rheumatologists
were younger than male rheumatologists. In general,
women were not only younger but also differently dis-
tributed within the groups of specialisation and subspe-
cialisation when compared to men. There were less
female surgeons than female rheumatologists or anaes-
thetists. Physicians working in a hospital were younger
than those in a private clinic.
When asked for the number of myofascial pain
patients treated, 163 (48.9%) of all physicians attended
more then four patients a week, 87 (26.1%) between one
and three patients a week, 39 (11.7%) between one and
three patients per month, 36 (10.8%) up to ten patients
a year and 6 (1.8%) physicians never saw myofascial
pain patients. There were no intergroup differences
regarding those distributions (p = 0.801).
When we asked how often patients were referred to
special pain centres, we found the following distribution:
82 (24.6%) of physicians never did, 89 (26.7%) up to ten
patients per year, 96 (28.8%) up to three patients per
month, 25 (7.5%) between one and three patients a
w e e ka n d2 6( 7 . 8 % )r e f e r r e dm o r et h a nf o u rp a t i e n t sa
week to a specialised pain centre. Pain therapists rarely
refer their patients to another centre (p < 0.001). For
detailed information see Table S1 (additional file 2).
Estimated importance of myofascial pain syndrome and
prevalence of myofascial trigger points
When asked for the importance of myofascial pain the
physicians mean score was 2.5 ± 1.4 (n = 330). There
were no significant differences among the respective
groups (p = 0.803), specialities (p = 0.578), genders (p =
0.294) or other demographic data.
Physicians estimated the prevalence of active trigger
points to 46.1 ± 27.4% (n = 329) in the overall popula-
tion and 52.8% ± 26.9 (n = 330) in their own patients.
Subjects from the pain congress rated these frequencies
higher than other physicians; 55.4 ± 22.2% in the overall
population (p < 0.001) and 63.4 ± 21.7% in their own
patients (p = 0.001). For detailed information see Table
S2 (additional file 3).
Prescription Rates of treatment options
Analgesics
Pharmacological approaches were the most common
treatment (1525 choices, i.e. a mean of 4.5 analgesics
evaluated per physician). Non steroidal anti-inflamma-
tory drugs or coxibs were the main analgesics (n = 304,
91.6%), followed by metamizol and paracetamol (n =
289, 87.0%), weak opioids (n = 271, 81.6%), antidepres-
sants (n = 240, 72.3%), strong opioids (n = 190, 57.2%)
or anticonvulsants (n = 175, 52.7%). Other drugs were
rarely used (n = 56, 16.9%), physicians named especially
muscle relaxants (n = 17, 5.1%) and flupirtine (n = 16,
4.8%). Detailed intra- and inter-group values are shown
in Figure 1 and Table S3 (additional file 4).
Physical therapy
Physical therapies were prescribed one-third less often
than analgesics (1118 choices, i.e. a mean of 3.4 physical
therapies evaluated per physician). Manual therapy was
prescribed most often, i.e. by 270 (81.1%) of all physi-
cians, followed by TENS (n = 242, 72.9%) and acupunc-
ture (n = 200; 60.2%). Ultrasound (n = 132, 39.8%),
percussion waves (n = 106, 31.9%) or dry needling (n =
96, 28.9%) were prescribed less often. Additional treat-
ments were chosen by 72 (21.7%) of all physicians.
These treatments were rather specified e.g. chiropractics
(n = 8), cryotherapy (n = 3) and osteopathy (n = 3) as
other physical therapy. Detailed intra- and inter-group
values are shown in Figure 1 and Table S3 (additional
file 4).
Injections
The use of injection techniques is less important in the
overall therapeutic concept (390 choices, i.e. a mean of
1.2 injections evaluated per physician). Injection of local
anaesthetics was mainly used (n = 236; 71.1%). Spinal
interventions (e.g. spinal cord stimulation, epidural
injection) was used by 102 (30.7%) whereas injection of
botulinum toxin was used by 41 (12.3%) of physicians.
Additional techniques (n = 11, 3.3%) were not specified.
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ure 1 and Table S3 (additional file 4).
Rating of treatment approaches
A 6-point scale (with 1 being excellent effective and 6
being worst) allowed physicians to rate the effectiveness
of the used treatment approaches. 54.3% of all physi-
cians surveyed stated current symptom-based treatment
options being insufficient. This opinion was more pro-
nounced in the rheumatologists group (77.3%) than
anaesthetists (49.2%) or orthopaedists (45.8%).
Analgesics
Muscle relaxants (2.1 ± 0.5) and flupirtine (1.6 ± 0.7) are
estimated as most effective analgesics. They form part of
additional assignable drugs (overall 2.3 ± 1.1 points). They
were followed by antidepressants (2.6 ± 1.0), non-steroidal
anti-inflammatory drugs or coxibs (2.7 ± 1.0), metamizol
or paracetamol (3.1 ± 1.0), weak opioids (3.1 ± 1.1), strong
opioids (3.2 ± 1.5) and anticonvulsants (3.2 ± 1.2). Detailed
intra- and intergroup data are shown in Figure 2 and
Table S4 (additional file 5).
There were significant intragroup differences regarding
the rating of treatment options for non-steroidal anti-
inflammatory drugs or coxibs (p = 0.002), weak and strong
opioids (p < 0.001), anticonvulsants (p = 0.024) and addi-
tional pharmacologic approaches (p = 0.006). Non-steroi-
dal anti-inflammatory drugs or coxibs were rated better
by orthopaedists when compared to pain therapists
(p = 0.018) or to rheumatologists (p = 0.001); weak and
strong opioids were rated less effective by pain therapists
than orthopaedists (p < 0.001) or rheumatologists (p <
0.01); pain therapists rated anticonvulsants worse than
orthopaedists (p = 0.008); Other pharmacologic treatments
scored better in the pain group then with orthopaedists
(p = 0.007) or rheumatologists (p = 0.018).
Physical therapies
Manual therapy was rated with an average of 2.3 ± 0.9.
Dry needling (2.4 ± 1.1) and acupuncture (2.4 ± 1.0)
were estimated with a similar effectiveness. TENS (2.6 ±
0.9) scored better than percussion waves (2.8 ± 1.2).
Ultrasound techniques were estimated being the less
effective therapeutic option (3.0 ± 1.2). Additional treat-
ments (e.g. chiropractics, osteopathy) were rated 2.0 ±
0.9. Detailed intra- and intergroup data are shown in
Figure 2 and Table S4 (additional file 5).
There were intragroup differences regarding the rating
of TENS (p = 0.001), manual therapy (p = 0.002) and acu-
puncture (p = 0.006). TENS got a better ranking by ortho-
paedists (p = 0.001) and pain therapists (p < 0.001) when
compared to rheumatologists. The same held for manual
therapy (p = 0.001, p = 0.1) and acupuncture (p = 0.008, p
= 0.002). Ultrasound was rated better by orthopaedists
than pain therapists (p = 0.033); Dry needling was rated
better by pain therapists than orthopaedists (p = 0.039) or
rheumatologists (p = 0.044).
Injections
Injection of local anaesthetics was rated with an average
of 2.3 ± 1.0 and injection of botulinum toxin scored
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Figure 1 Prescription Rate. demonstrates the physician estimated prescription rate of different therapeutic options in the treatment of
myofascial pain. Circles indicate the overall average; the prescription rates of three subgroups (Pain therapists, rheumatologists and
orthopaedists) are shown by triangles or squares (please refer to legend). Data are expressed in percent (%). TENS: transcutaneous electrical
stimulation.
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Additional but unspecified injections scored 1.9 ± 0.5.
Detailed intra- and intergroup data are shown in Figure
2 and Table S4 (additional file 5).
There were intragroup differences regarding the rating
of injection of local anaesthetics (p = 0.008). This con-
cerned the rheumatologists group when compared to
pain therapists (p = 0.032) or orthopaedists (p = 0.002).
Injections were rated differently by orthopaedists and
rheumatologists (p = 0.021).
Correlations between participant characteristics and
treatment approaches
A gender effect could be demonstrated for the use of
spinal interventions (p = 0.049), which is rarely used by
women, while they prefer manual therapy (p = 0.019).
Physicians younger than 35 years rated the use of
weak (p = 0.002) and strong opioids (p = 0.009) less
effective than those older than 65 years.
Working place-related effects appeared different: phy-
sicians employed at district hospitals (n = 113) esti-
mated non-steroidal anti-inflammatory drugs or coxibs
more effective than physicians working in a private
practice (n = 160, p = 0.018).
Comparing the ratings of residents and consultants,
it became evident that residents evaluated weak
(p = 0.004) and strong opioids (p = 0.001), antidepres-
sants (p = 0.049) and dry needling (p = 0.042) less
effective.
Discussion
To our knowledge, the present study is the first physi-
cians survey that estimates the prevalence and clinical
importance of myofascial pain and the utilization rate
and physician rated effectiveness of the most common
treatment options. Our data suggests that German phy-
sicians that treat various pain issues considered myofas-
cial pain a highly prevalent condition. Though,
prescription rate and estimated effectiveness of pre-
scribed treatments showed significant discrepancies: the
most frequently prescribed treatments were not rated
the most effective (Figures 1, 2). In addition, our data
revealed significant discrepancies regarding the treat-
ment of myofascial pain in different fields of
specialisation.
Implications for treatment options
This current survey demonstrates that physicians esti-
mated the effectiveness of frequently prescribed analge-
sics as unsatisfactory. For example commonly used
analgesics such as NSAID and coxibs, metamizol and
paracetamol and weak opioids were estimated moder-
ately in their effectiveness. This lack of concordance
between frequently prescribed treatments and perceived
effectiveness reflects the lack of scientific evidence and
available treatment guidelines. Consensus is also requi-
site among researchers to define and describe myofascial
pain using standard terminology and validated
NSAIDs' and coxibes
Metamizol and paracetamol
Weak opioids
Antidepressants
Strong opioids
Anticonvulsants
Others
Muscle Relaxants
Flupirtine
Manual therapy
TENS
Acupuncture
Ultrasound
Percussion waves
Dry needling
Others
Injection of local anaesthetics
Spinal interventions
Injection of botulinum toxin
Others
4.0 3.5 3.0 2.5 2.0 1.5 1.0
Effectiveness Rating Score (range 1-6)
Analgesics
Physical therapies
Injections
6.0
u
n
e
f
f
e
c
t
i
v
e
e
x
c
e
l
l
e
n
t
 mean
 pain therapists
 orthopaedists 
 rheumatologists 
Figure 2 Ratings of Treatment Options. demonstrates the physician estimated efficacy of different therapeutic options in the treatment of
myofascial pain on a 6-fold scale (with 1 being “excellently effective” and 6 being “ineffective”). Ratings towards the lower ranks on the value
axis indicate a higher estimated effectiveness. Data are expressed as mean ± SD. (*), (**) and (***) express the different levels of significance p <
0.05, 0.01 and 0.001. Between-group differences were examined with Kruskal-Wallis tests, using the Mann-Whitney U tests for post-hoc two-
group comparisons. Stars are placed upon the confirmed group, respectively. TENS: transcutaneous electrical stimulation.
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could relate to the confusion and controversy among
physicians regarding the treatment of myofascial pain
disorders. At least, according to our survey, physicians
seem to be aware of the ambiguity of their treatment
approaches effectiveness. However Wheeler reports that
most experts recommend medication as an adjunctive
treatment to injection and exercise therapy in acute and
chronic musculoskeletal pain.
Similar observations have been made by Tsang and
her colleagues in the treatment of chronic vascular dis-
ease. A knowledge gap caused by lack of awareness of
the evidence or familiarity with current treatments leads
to a so called evidence-to-practice care gap [24].
We observed that the perceived effectiveness of some
treatments that require specialized education and addi-
tional experience, including acupuncture, TENS, dry
needling or injections varied among specialist. In gen-
eral, these techniques were rated to be controversial;
especially by physicians not familiar with these practical
treatments. For example, ratings for injection techniques
(e.g. spinal interventions) differed in between groups,
what could be explained by a particular enhanced use of
invasive methods in the respective clinical fields. The
choice of treatment might depend on the professional
career of the physicians. For example orthopaedists, by
specialisation familiar with surgical techniques, were
estimating injections better. In contrast, rheumatologists,
familiar with pharmacologic treatments, estimated phar-
macologic approaches better. There were also differ-
ences regarding the rating of group related treatments
such as ultrasound and percussion waves that could be
due to different educational access. Taken together
these data suggest that the estimated efficacy of treat-
ment options for myofascial pain syndrome is mostly
influenced by the speciality-related training and educa-
tion of the physicians.
In addition our data show that other physician-related
parameters may influence the choice of treatment. We
analysed the impact of working place or status of specia-
lisation. While physicians in the pain congress group
mainly worked in hospitals, those members that had
chosen a private practice as their working place rated
treatments differently, which might reflect the differ-
ences in work experience in these groups. It might also
influence the choice and rating of treatments. We could
also demonstrate that use and evaluation of treatments
are influenced by the status of specialisation. It might
also be possible that previously learned strategies are
kept out of mind. It has been shown that physicians
reconsider the use of evidence-based treatments by sim-
ple patient-specific prompting [24].
Access to education in the treatment of myofascial
pain seems to be an important fact whilst improving
diagnosis and treatment of myofascial pain. Bishop et al.
could recently demonstrate diversity of the attitudes of
general practitioners and physiotherapists in the United
Kingdom (UK) towards low back pain patients. Against
the line of clinical guidelines a quarter of respondents
believed in avoidance of physical activity or the need to
be off work as part of treatment regimen [25]. This sug-
gests that the lack of availability of recommendations or
expert opinions to health professionals is a widespread
phenomenon. As a corollary, those wishing to accelerate
the adoption of new evidence may need to undertake
more active promotion [26], in order to obtain generally
accepted guidelines [27].
Implications for clinical practice and for future research
It remains interesting why physicians estimated seldom
used pharmacologic remedies as very effective, e.g. mus-
cle relaxants, chiropractics or flupirtine. Flupirtine for
example appeared as a scientifically promising but not
yet prevalent treatment option [28]. Large clinical trials
for the use of flupirtine in the treatment of myofascial
pain are lacking. Yet, prescription patterns and per-
ceived effectiveness of these rarely used treatments in
the view of treating physicians have still to be evaluated.
To conclude, a facilitated access to the latest outcome
in pain research might be desirable to get an overview
of potential treatment options.
The majority of physicians, even whilst prescribing,
characterized the available symptomatic treatment
options as insufficient. This might also reflect the chal-
lenge to understand the sophisticated pathogenic path-
ways that may lead to myofascial pain syndromes. The
complexity of pathogenesis might also be expressed
regarding the multitude of different available treatment
approaches. This survey did e.g. not approach the psy-
chosocial aspects of treatments event though it is sup-
posed that the occurrence of depression has been
related to pain syndromes of the joints and musculoske-
letal system [29]. It is commonly understood that
chronic myofascial pain may be a consequence of
a complex stress response that extends beyond the
nervous system and contributes to the experience of
pain [30].
In addition, physicians estimated the prevalence of active
trigger points. Almost every second person is considered
having active trigger points, thus supporting physicians
opinion considering myofascial pain a highly prevalent
condition. Myofascial trigger points have been described
as a ‘common cause of pain in clinical practice’ and an
‘extremely common, yet commonly overlooked’ source of
musculoskeletal disorders [31]. The evidence of Simon
a n dT r a v e l l ss t a t e m e n t ,a sw e l la so u rr e s u l t sb a s e do n
physicians opinions and experience, is limited as there is
no available diagnostic gold standard for mTrPs based on
Fleckenstein et al. BMC Musculoskeletal Disorders 2010, 11:32
http://www.biomedcentral.com/1471-2474/11/32
Page 6 of 9a laboratory test or imaging technique [3]. Diagnosis is
confirmed by clinical history and physical examination,
free from systemic inflammatory, autoimmune or other
locomotor system disease.
Clinically, an active (symptom-producing) central
myofascial trigger point can be defined as a hyperirrita-
ble nodule of spot tenderness in a palpable taut band of
skeletal muscle. The spot is a site of exquisite tender-
ness to palpation from which a local twitch response
can be elicited when appropriately stimulated, that refers
pain to a distance, and that can cause distant motor and
autonomic effects.
These clinically findings have not been proven to be
reliable, as stated in a recent review by Lucas et al. [32].
However there is no validated list of diagnostic criteria
for mTrPs. Two pilot studies with a small number of
subjects evaluating various diagnostic tests [33,34]
reported good overall interrater reliability. They
reported examining for a taut band, spot tenderness, a
palpable nodule, elicited referred pain, and the local
twitch response [3]. Licht et al. recently demonstrated
that some ‘key’ diagnostic criteria acc. to Simons and
Travell [31] of myofascial trigger points could reliably
be found by two different examiners in a smaller sample
group [35]. Harden et al. presented 2000 a list of addi-
tional 31 signs and symptoms that are related to myo-
fascial disorders [36].
Our data demonstrate that active myofascial trigger
points are considered prevalent and related to myofas-
cial pain by the physicians. Hence, the lack of concor-
dance in this field is limiting the conclusion how far this
observation may contribute to the thesis that trigger
point diagnosis is reliable.
Methodological considerations
It is commonly understood that chronic myofascial pain
may be a consequence of a complex stress response that
extends beyond the nervous system and contributes to
the experience of pain.
As we chose personal contact instead of postal distri-
bution almost everyone asked responded to the ques-
tionnaire (response-rate > 95%).
In any attempt to examine the clinical practice of
myofascial pain syndrome management for an entire
population of physicians in a country, a questionnaire
study is the most feasible method. However, we do not
know to what extent the physicians’ responses represent
their actual practice, or whether is their perception of
professional behaviour. It remains an open question
whether the physicians’ skills and abilities to treat myo-
fascial pain syndrome are reflected in the answers and
ratings to the questions. It is our belief that the ques-
tionnaire addresses central elements in myofascial pain
management. The only reliable way to measure
prescribing practices is to analyse the actual process in
detail. But even then, this approach would not provide
an understanding of the perceived effectiveness of the
prescribed treatments.
Our questionnaire regarded the myofascial pain syn-
drome as a single entity. One reason was the current
lack of strict classification criteria for distinct clinical
entities. The participants of this study might handle dif-
ferent aspects of the myofascial pain syndrome and
therefore choose different treatments. We took the
approach on introducing questions on myofascial trigger
points at the beginning of the questionnaire to help
ensure that the physicians responses related to the treat-
ment of myofascial pain syndrome rather than other
soft tissue pain conditions such as fibromyalgia.
The questionnaire has not undergone formal valida-
tion. The objective of this study was to analyse and pro-
vide an overview of the diversified customs of German
physicians in the treatment of myofascial pain syn-
drome. Given the purpose of the questionnaire, valida-
tion is not necessary.
Conclusions
The results of this survey demonstrate that there is no
agreement amongst German specialist in the utilization
and perceived effectiveness of the various common
treatment options for myofascial pain. In view the low
rating of effectiveness, physicians seem to be aware of
this drawback. We believe that guidelines for the treat-
ment of myofascial pain syndrome are necessary.
Neither standard diagnostic procedures to identify myo-
fascial pain nor discriminating variables to distinguish
the different entities of myofascial pain syndrome are
available. Therefore we conclude that multiple diagnos-
tic approaches may lead to therapeutic confusion.
All things considered, beside education in the manage-
ment of myofascial pain syndrome and enhancing man-
ual skills, clinical investigation is necessary to develop
standard guidelines in the diagnosis and treatment of
myofascial pain syndrome.
Additional file 1: Questionnaire on myofascial pain. Please find
detailed description of the questionnaire within the manuscript.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-2474-11-
32-S1.DOC]
Additional file 2: Table S1 - Demographic and participants
characteristics (mean ± SD or in %). Table S1 provides the
demographic data of physicians dealing with myofascial pain: age,
gender, field of specialisation, subspecialisation, employment centre and
status of specialisation. We asked for the physician’s average number of
treated myofascial pain patients (Treatment ratio) and the number of
patients referred to specialised pain centres (Referral Ratio). Data are
expressed as mean ± SD or as total count (n) and in percent (%).
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-2474-11-
32-S2.DOC]
Fleckenstein et al. BMC Musculoskeletal Disorders 2010, 11:32
http://www.biomedcentral.com/1471-2474/11/32
Page 7 of 9Additional file 3: Table S2 - Estimated prevalence (mean ± SD).
Table S2 provides the physician estimated importance of myofascial pain
in the general population on a six-point scale (with 1 being a “very
common problem”). Additionally the physician estimated prevalence of
active trigger points in the general population and their respective
patients in percent (%) is given. Data are expressed as mean ± SD.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-2474-11-
32-S3.DOC]
Additional file 4: Table S3 - Prescription Rate of Treatment Options
(in %). Table S3 indicates the physician estimated prescription rate of
different therapeutic options in the treatment of myofascial pain. Data
are expressed in percent (%). TENS: transcutaneous electrical stimulation.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-2474-11-
32-S4.DOC]
Additional file 5: Table S4 - Ratings (1-6) of treatment options
(mean ± SD). Table S4 indicates the physician estimated efficacy of
different therapeutic options in the treatment of myofascial pain on a 6-
fold scale (with 1 being “excellently effective” and 6 being “ineffective”).
Data are expressed as mean ± SD. TENS: transcutaneous electrical
stimulation.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-2474-11-
32-S5.DOC]
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